Up‐dosing of reslizumab in severe asthmatics with persistent sputum eosinophilia: A feasibility study.

This document presents two studies on the use of reslizumab as a treatment for severe asthma with persistent sputum eosinophilia. The first study examines the effects of higher doses of reslizumab on sputum eosinophils in patients who did not respond to the standard dose. The study found that 40% of patients achieved normalized sputum eosinophils after four infusions, while the remaining 60% required a higher dose. The second study focuses on the use of inhaled corticosteroids and found that higher doses of reslizumab led to better suppression of eosinophils and improved asthma control. The studies highlight the potential benefits of higher doses of reslizumab in treating severe asthma with persistent sputum eosinophilia and the importance of assessing and classifying patients based on sputum cytokines. [Extracted from the article]